Pharmacological modulation of LXRβ may offer a novel therapeutic strategy for restoring neural circuit stability in FCD, highlighting its potential as a molecular target for intervention in drug‐resistant epilepsy. Here, NR1H2 is linked to fleck corneal dystrophy.